Sodium Iodide I 123 200 uCi Capsule, Gelatin Coated, 5-count
🆔 Identity & classification
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Where does this data come from?
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII HX1032V43M
Sodium thiosulfate is a salt compound used in medicines as a buffer and pH regulator. It helps stabilize the medication and may also serve as a preservative or antioxidant to maintain product quality.
-
UNII C151H8M554
A natural sugar derived from sugar cane or sugar beets. It's used as a sweetener, filler, and binder to improve taste, add bulk, and help hold tablet or capsule ingredients together.
2 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Sodium Iodide I 123 200 uCithis 48815-1002-05 | Cardinal | 5 capsules | — | AA | FDA listed | — |
| Sodium Iodide I 123 200 uCi 69945-0602-20 | Curium | 1 capsule | — | AA | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
The FDA lists approved generic versions of this medicine, but that does not always mean a pharmacy can get one today. Patent rules, launch agreements, supply and pricing can affect when generics actually arrive.
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 48815-1002-01 | 1 VIAL, PLASTIC in 1 CAN (48815-1002-1) / 1 CAPSULE, GELATIN COATED in 1 VIAL, PLASTIC | 2003-01-02 | Active |
| 48815-1002-05 You're viewing this | 1 VIAL, PLASTIC in 1 CAN (48815-1002-5) / 5 CAPSULE, GELATIN COATED in 1 VIAL, PLASTIC | 2003-01-02 | Active |
Pack size FAQ
What quantity is in NDC 48815-1002-05?
What is the difference between NDC 48815-1002-05 and NDC 48815-1002-01?
What NDC number is used to bill for this package of Sodium Iodide I 123 200 uCi Capsule, Gelatin Coated?
🧭 About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
Questions about this listing
Why is there no price listed?
Is the NDC printed on the package the same as the 11-digit billing NDC?
What do the three segments of this NDC mean?
Is this package still being marketed?
Does this product come in other package sizes?
Who lists this product with the FDA?
Do I need a prescription for this product?
Where does this data come from?
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATION AND USE Administration of Sodium Iodide I 123 is indicated as a diagnostic procedure to be used in evaluating thyroid function and/or morphology.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION The recommended oral dose for the average patient (70 kg) is 3.7 to
14.8MBq (100-400 µCi). The lower part of the dosage range
3.7 MBq (100 µCi) is recommended for uptake studies alone, and the higher part
14.8MBq (400 µCi) for thyroid imaging. The determination of I 123 concentration in the thyroid gland may be initiated at six hours after administering the dose and should be measured in accordance with standardized procedures. The patient dose should be measured by a suitable radioactive calibration system immediately prior to administration.
The capsules can be utilized up to thirty (30) hours after calibration time and date. Thereafter, discard the capsules in accordance with standard safety procedures. The user should wear waterproof gloves at all times when handling the capsules or container.
Radiation Dosimetry The estimated absorbed radiation doses to several organs of an average patient (70 kg) from oral administration of the maximum dose of
14.8MBq (400 µCi) of I 123 are shown in Table 4 for thyroid uptakes of 5, 15, and 25%. For comparison at these three values of thyroid uptake, the estimated radiation doses from doses of
3.7MBq (100 µCi) I 131, also used as thyroid imaging agent, are also included. Table 4 Radiation Dose Estimates as a Function of Maximum Thyroid Uptake for I 123* Sodium Iodide At Time of Calibration and Expiry Compared to I 131 *Concentration at Time of Calibration: 97% I 123, 2.9% I 125, 0.1% Te 121 Concentration at Time of Expiry: 87.2% I 123, 12.4% I 125, 0.4% Te 121 All Iodine Kinetics treated as in MIRD Dose Estimate Report 5. Bladder voiding interval, 4.8 hours.
Tellurium 121 dosimetry taken from ICRP 30. Target Organ Maximum Thyroid Uptake (%) Estimated Radiation Absorbed Doses I 123 mGy/14.8 MBq (rads/400 µCi) I 131 mGy/3.7 MBq (rads/100 µCi) TOC TOE Thyroid 5 25 (2.5) 75 (7.5) 260 (26) 15 77 (7.7) 230 (23) 780 (78) 25 130 (13) 410 (41) 1300 (130) Liver 5 0.089 (0.0089) 0.13 (0.013) 0.16 (0.016) 15 0.10 (0.010) 0.18 (0.018) 0.28 (0.028) 25 0.11 (0.011) 0.24 (0.024) 0.41 (0.041) Ovaries 5 0.18 (0.018) 0.19 (0.019) 0.18 (0.018) 15 0.17 (0.017) 0.18 (0.018) 0.18 (0.018) 25 0.16 (0.016) 0.18 (0.018) 0.17 (0.017) Red Marrow 5 0.12 (0.012) 0.16 (0.016) 0.15 (0.015) 15 0.12 (0.012) 0.18 (0.018) 0.21 (0.021) 25 0.13 (0.013) 0.19 (0.019) 0.27 (0.027) Stomach Wall 5 0.96 (0.096) 0.98 (0.098) 1.7 (0.17) 15 0.89 (0.089) 0.91 (0.091) 1.5 (0.15) 25 0.82 (0.082) 0.85 (0.085) 1.4 (0.14) Small Intestine 5 0.70 (0.070) 0.71 (0.071) 1.2 (0.12) 15 0.65 (0.065) 0.67 (0.067) 1.1 (0.11) 25 0.60 (0.060) 0.62 (0.062) 0.99 (0.099) Testes 5 0.076 (0.0076) 0.089 (0.0089) 0.12 (0.012) 15 0.072 (0.0072) 0.087 (0.0087) 0.12 (0.012) 25 0.068 (0.0068) 0.085 (0.0085) 0.12 (0.012) Bladder 5 1.7 (0.17) 1.7 (0.17) 2.9 (0.29) 15 1.6 (0.16) 1.6 (0.16) 2.7 (0.27) 25 1.4 (0.14) 1.5 (0.15) 2.4 (0.24) Skeleton 5 0.11 (0.011) 0.16 (0.016) 0.12 (0.012) 15 0.12 (0.012) 0.18 (0.018) 0.18 (0.018) 25 0.14 (0.014) 0.21 (0.021) 0.24 (0.024) Total Body 5 0.11 (0.011) 0.16 (0.016) 0.24 (0.024) 15 0.14 (0.014) 0.25 (0.025) 0.47 (0.047) 25 0.17 (0.017) 0.35 (0.035) 0.70 (0.070)
⛔ Contraindications ▾
CONTRAINDICATIONS To date there are no known contraindications to the use of Sodium Iodide I 123 capsules.
⚠️ Warnings ▾
WARNINGS Females of childbearing age and children under 18 should not be studied unless the benefits anticipated from the performance of the test outweigh the possible risk of exposure to the amount of ionizing radiation associated with the test.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Although rare, reactions associated with the administration of Sodium Iodide isotopes for diagnostic use include, in decreasing order of frequency, nausea, vomiting, chest pain, tachycardia, itching skin, rash and hives.
🧒 Pediatric Use ▾
Pediatric Use Safety and effectiveness in children have not been established.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Sodium Iodide I 123 is readily absorbed from the upper gastrointestinal tract. Following absorption, the iodide is distributed primarily within the extracellular fluid of the body. It is trapped and organically bound by the thyroid and concentrated by the stomach, choroid plexus and salivary glands.
It is excreted by the kidneys. The fraction of the administered dose which is accumulated in the thyroid gland may be a measure of thyroid function in the absence of unusually high or low iodine intake or administration of certain drugs which influence iodine accumulation by the thyroid gland. Accordingly, the patient should be questioned carefully regarding previous medication and/or procedures involving radiographic media.
Normal subjects can accumulate approximately 10-50% of the administered iodine dose in the thyroid gland, however, the normal and abnormal ranges are established by individual physician's criteria. The mapping (imaging) of Sodium Iodide I 123 distribution in the thyroid gland may provide useful information concerning thyroid anatomy and definition of normal and/or abnormal functioning of tissue within the gland.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Sodium Iodide I 123 is supplied as capsules for oral administration in strengths of
3.7 MBq (100 µCi) and
7.4MBq (200 µCi) at time of calibration. Each gelatin capsule contains 0.45 - 0.65 g of sucrose. The capsules are packaged in plastic vials containing either one or five capsules of a single strength per vial.
The plastic vial is packaged in a lead shield with a label identical to that affixed to the plastic vial. A package insert is supplied with each lead shield. The -I (Iodine) content for a 100 µCi capsule is 5.2 ng and the -I content for a 200 µCi capsule is 10.4 ng at TOC.
Dispense and preserve capsules in well-closed containers that are adequately shielded. Store at room temperature, below 86°F. The contents of the capsules are radioactive.
Adequate shielding and handling precautions must be maintained. THIS PACKAGE INSERT ISSUED APRIL 2018 Cardinal Health Denver, CO 80011 (303) 343-6800 Sodium Iodide I 123 1-020-16
📋 Description ▾
DESCRIPTION Sodium Iodide I 123 (Na 123 I) for diagnostic use is supplied in capsules for oral administration. The capsules are available in strengths of 3.7 and 7.4 megabecquerels (MBq) (100 and 200 μCi) I 123 at time of calibration. Each capsule contains 0.3 µg - 3 µg Sodium Thiosulfate as a stabilizer.
The radionuclidic composition at calibration is not less than 97.0 percent I 123, not more than 2.9 percent I 125 and not more than 0.1 percent all others (I 121 or Te 121.) The radionuclidic composition at expiration time is not less than 87.2 percent I 123, not more than 12.4 percent I 125 and not more than 0.4 percent all others. The ratio of the concentration of I 123 and I 125 changes with time. Graph 1 shows the maximum concentration of each as a function of time.
Graph 1 Radionuclidic Concentration of I 123 and I 125 Physical Characteristics Sodium Iodide I 123 decays by electron capture with a physical half-life of 13.2 hours. The photon that is useful for detection and imaging studies is listed in Table 1 . Table 1 Principal Radiation Emission Data 1 1 Kocher, David C., Radioactive Decay Data Tables, DOE/TIC-11026, 122, (1981) Radiation Mean %/Disintegration Mean Energy (keV) Gamma-2 83.4 159 External Radiation The specific gamma ray constant for I 123 is
1.6R/hr-mCi at 1 cm. The first half value thickness of lead (Pb) for I 123 is 0.005 cm. A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from the interposition of various thicknesses of Pb is shown in Table 2 .
For example, the use of 1.63 cm of lead will decrease the external radiation exposure by a factor of about 1,000. Table 2 Radiation Attenuation by Lead Shielding 2 2 Shleien, Bernard, The Health Physics and Radiological Health Handbook, Table 6.1.2, 169, (1992) Shield Thickness (Pb), cm Coefficient of Attenuation 0.036 0.5 0.120 10 -1 0.240 10 -2 0.358 10 -3 0.477 10 -4 Note that these estimates of attenuation do not take into consideration the presence of contaminants. To correct for physical decay of I 123, the fractions that remain at selected intervals after the time of calibration are shown in Table 3 .
Table 3 Sodium Iodide I 123 Decay Chart: Half-Life
13.2Hours *Time of Calibration Hours Fraction Remaining Hours Fraction Remaining 0* 1.000 18 .389 3 .854 21 .332 6 .730 24 .284 9 .623 27 .242 12 .535 30 .207 15 .455 Graph 1